Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse

International Journal of Toxicology

Volumn 24, Issue SUPPL. 5, 2005, Pages 301-311

  Nesfield, Sarah R ^a,e   Clarke, Christopher J ^a   Hoivik, Debie J ^b   Miller, Richard T ^b   Allen, Jane S ^c   Selinger, Krzysztof ^d   Santostefano, Michael J ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c Jane Allen Consulting Inc   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

^e NONE   (United Kingdom)

Author keywords

Carcinogenicity; Carcinoma; Clofibrate; Mice; NMU; rasH2

Indexed keywords

CLOFIBRATE; METHYLNITROSOUREA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CANCER RISK; CONTROLLED STUDY; DRUG CARCINOGENICITY; FEMALE; GENETIC EPIGENESIS; GENOTOXICITY; HARDER GLAND; HISTOPATHOLOGY; LIVER CELL CARCINOMA; MALE; MODEL; MOUSE; NONHUMAN; ONCOGENE H RAS; PROMOTER REGION; RISK ASSESSMENT; TOXICOKINETICS; TRANSGENIC MOUSE; CARCINOGENICITY; DISEASE ASSOCIATION; DOSE RESPONSE; FEEDING; KIDNEY; LUNG; MOUSE STRAIN; SKIN; SPLEEN; TAIL; THYMUS; UTERUS;

ANIMALIA; MUS MUSCULUS;

ANIMALS; CARCINOGENICITY TESTS; CLOFIBRATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE NEOPLASMS; FEMALE; GENES, RAS; HARDERIAN GLAND; HUMANS; INTUBATION, GASTROINTESTINAL; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, TRANSGENIC; PEROXISOME PROLIFERATORS; RISK ASSESSMENT; TIME FACTORS;

EID: 27544502134     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1080/10915810500210278     Document Type: Article

References (41)

1. Amacher, D. E., R. Beck, S. J. Schomaker, C. V. Kenny, and G. Hajian. 1997. Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat. Toxicol. Appl. Pharmacol. 142:143-150.
2. Blain, P. G. 2003. Committee on arcinogenicity of chemicals in food, consumer products and the environment. Statement on ILSI/HESI research programme on alternative cancer models. Toxicol. Pathol. 31:254-257.
3. Cayen, M. N. 1980. Metabolic disposition of clofibrate. Rev. Drug Metab. Drug Interact. 3:1-27
4. Cheung, C., T. E. Akiyama, J. M. Ward, C. J. Nicol, L. Feigenbaum, C. Vinson, and F. J. Gonzalez. 2004. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res. 64:3849-3854.
5. Conover, W. J. 1980. Practical nonparametric statistics. New York: John Wiley and Sons.
6. da Silva Franchi, C. A., M. M. Bacchi, C. R. Padovani, and J. L. de Camargo. 2003. Thymic lymphomas in Wistar rats exposed to N-methyl-N-nitrosourea (MNU). Cancer Sci. 94:240-243.
7. Dass, S. B., T. J. Bucci, R. H. Heflich, and D. A. Casciano. 1999. Evaluation of the transgenic p53+/- mouse for detecting genotoxic liver carcinogens in a short-term bioassay. Cancer Lett. 23:81-85.
8. Gonzalez, F. J., J. M. Peters, and R. C. Cattley. 1998. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. J. Natl. Cancer Inst. 90:1702-1709.
9. Greaves, P. 1990. Histopathology of preclinical toxicity studies. The Netherlands: Elsevier Science Publishers.
10. +/- mouse. Int. J. Toxicol. 24:349-356.
11. Hoivik, D. J., C. W. Qualls Jr., R. C. Mirabile, N. F. Cariello, C. L. Kimbrough, H. M. Colton, S. P. Anderson, M. J. Santostefano, R. J. Morgan, R. R. Dahl, A. R. Brown, Z. Zhao, P. N. Mudd Jr., W. B. Oliver Jr., H. R. Brown, and R. T. Miller. 2004. Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis 5:1757-1769.
12. International Agency for Research on Cancer (IARC). 1978. Monographs on the evaluation of the carcinogenic risk of chemicals to man, I, 1972-present, V17 241. Geneva: World Health Organization.
13. Jones, T. C., J. A. Popp, and U. Mohr. 1997. Monographs on pathology of laboratory animals: Digestive system. Germany: Springer-Verlag.
14. Klaunig, J. E., M. A. Babich, K. P. Baetcke, J. C. Cook, J. C. Corton, R. M. David, J. G. DeLuca, D. Y. Lai, R. H. McKee, J. M. Peters, R. A. Roberts, and P. A. Fenner-Crisp. 2003. PPARalpha agonist-induced rodent tumors: Modes of action and human relevance. Crit. Rev. Toxicol. 33:655-780.
15. Kluwe, W. M., J. K. Haseman, J. F. Douglas, and J. E. Huff. 1982. The carcinogenicity of dietary di(2-ethylhexyl) phthalate (DEHP) in Fischer 344 rats and B6C3F1 mice. J. Toxicol. Environ. Health 10:797-815.
16. Mangues, R., J. M. Kahn, I. Seidman, and A. Pellicer. 1994. An overexpressed N-ras proto-oncogene cooperates with N-methylnitrosourea in mouse mammary carcinogenesis. Cancer Res. 54:6395-6401.
17. Maronpot, R. R. 1999. Tumor incidences in control B6C3F1 mice from NTP carcinogenicity studies. In Pathology of the mouse, reference and atlas., ed. Maronpot, R. R., G. A. Boorman, and B. W. Gaul. Vienna, IL: Atlas Cache River Press.
18. Milton, M. N., C. R. Elcombe, and G. G. Gibson. 1990. On the mechanism of induction of microsomal cytochrome P450IVA1 and peroxisome proliferation in rat liver by clofibrate. Biochem. Pharmacol. 40:2727-2732.
19. Mitsumori, K., H. Koizumi, T. Nomura, and S. Yamamoto. 1998. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Toxicol. Pathol. 26:520-531.
20. NDA. 1993. Summary of basis for approval, Food and Drug Administration. 19-304.
21. Nesfield, S. R., T. C. Williams, D. J. Hoivik, R. T. Miller, J. S. Allen, K. Selinger, D. Rickert, and M. J. Santostefano. 2005. Evaluation of the carcinogenic potential of clofibrate in the neonatal mouse. Int. J. Toxicol. 24:341-348.
22. Overturf, M. L., and D. S. Loose-Mitchell. 1992. In vivo models: The choice of the experimental animal model for analysis of lipoproteins and atherosclerosis. Curr. Opin. Lipidol. 3:179-185.
23. Qin, X., H. Zhou, L. Liu, and S.L. Gerson. 1999. Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis. Carcinogenesis 20:1667-1673.
24. Reddy, J. K., S. Rao, and D. E. Moody. 1976. Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator. Cancer Res. 36:1211-1217.
25. Robinson, D. E., and J. S. MacDonald. 2001. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. Toxicol. Pathol. 29(Suppl.)13-19.
26. Shilkaitis, A., A. Green, V. Steele, R. Lubet, G. Kelloff, and K. Christov. 2000. Neoplastic transformation of mammary epithelial cells in rats is associated with decreased apoptotic cell death. Carcinogenesis 21:227-233.
27. Simpson, A. E. 1997. The cytochrome P450 4 (CYP4) family. Gen. Pharmacol. 28:351-359.
28. Snedecor, G. W., and W. G. Cochran. 1968. Statistical methods. Ames, Iowa: Iowa State University Press.
29. Spalding, J. W., J. E. French, R. R. Tice, M. Furedi-Machacek, J. K. Haseman, and R. W. Tennant. 1999. Development of a transgenic mouse model for Carcinogenesis bioassays: Evaluation of chemically induced skin tumors in Tg.AC mice. Toxicol. Sci. 49:241-254.
30. Storer, R. D., J. E. French, J. Haseman, G. Hajian, E. K. LeGrand, G. G. Long, L. A. Mixson, R. Ochoa, J. E. Sagartz, and K. A. Soper 2001. P53+/- hemizygous knockout mouse: Overview of available data. Toxicol. Pathol. 29(Suppl):30-50.
31. Tamaoki, N. 2001. The rasH2 transgenic mouse: Nature of the model and mechanistic studies on tumorigenesis. Toxicol. Pathol. 29(Suppl.):81-89.
32. Tennant, R. W., J. E. French, and J. W. Spalding. 1995. Identification of chemical carcinogens and assessing potential risk in short term bioassays using transgenic mouse models. Environ. Health Perspect. 103:942-950.
33. Tennant, R. W., J. Spalding, and J. E. French. 1996. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat. Res. 365:119-127.
34. Tennant, R. W., S. Stasiewicz, W. C. Eastin, J. H. Mennear, and J. W. Spalding. 2001. The Tg.AC (v-Ha-ras) transgenic mouse: Nature of the model. Toxicol. Pathol. 29(Suppl.):51-59.
35. +/- mouse. Int. J. Toxicol. 24:289-299.
36. Torrey, C. E., H. G. Wall, J. A. Campbell, P. Kwanyuen, D. J. Hoivik, R. T. Miller, J. S. Allen, M. J. Jayo, K. Selinger, and M. J. Santostefano. 2005b. Evaluation of the carcinogenic potential of Clofibrate in the FVB/Tg.AC mouse after dermal application - Part II. Int. J. Toxicol. 24:327-339.
37. Torrey, C. E., H. G. Wall, J. A. Campbell, P. Kwanyuen, D. J. Hoivik, R. T. Miller, J. S. Allen, M. J. Jayo, K. Selinger, P. M. Savina, and M. J. Santostefano. 2005c. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after oral administration - Part I. Int. J. Toxicol. 24:313-325.
38. Yamamoto, S., Y. Hayashi, K. Mitsumori, and T. Nomura. 1997. Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene. Lab. Animal Sci. 47:121-126.
39. Yamamoto, S., K. Urano, and T. Nomura. 1998. Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Toxicol. Lett. 102-103:473-478.
40. Yki-Jarvinen, H. 2004. Thiazolidinediones. N. Engl. J. Med. 351:1106-1118.
41. Yuge, K., H. Nambu, H. Senzaki, I. Nakao, H. Miki, M. Uyama, and A. Tsubara. 1996. N-methyl-N-nitrosourea-induced photoreceptor apoptosis in the mouse retina. In Vivo 10:483-488.